TCGA-AO-A0J3-01A-11R-A034-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 22
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.450
- DNA_REPAIR+0.390
- E2F_TARGETS+0.340
- G2M_CHECKPOINT+0.300
- PANCREAS_BETA_CELLS+0.300
- MYC_TARGETS_V1+0.270
- UNFOLDED_PROTEIN_RESPONSE+0.230
- HEME_METABOLISM+0.160
- SPERMATOGENESIS+0.160
- MYC_TARGETS_V2+0.150
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.640
- INFLAMMATORY_RESPONSE-0.520
- ALLOGRAFT_REJECTION-0.500
- NOTCH_SIGNALING-0.480
- TNFA_SIGNALING_VIA_NFKB-0.460
- APICAL_SURFACE-0.440
- COAGULATION-0.440
- IL6_JAK_STAT3_SIGNALING-0.430
- KRAS_SIGNALING_UP-0.400
- ANGIOGENESIS-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BSR_04_0040_A3_S71 | — | B | 0.921 |
| 2 | BS_VA5T4KAA | medulloblastoma | — | 0.916 |
| 3 | BS_H4B5Y6S0 | medulloblastoma | — | 0.915 |
| 4 | BS_HKZENFDA | medulloblastoma | — | 0.912 |
| 5 | SRR4195684 | — | — | 0.910 |
| 6 | TCGA-66-2756-01A-01R-0851-07 | — | cohortA3 | 0.907 |
| 7 | SRR35579806 | — | B | 0.907 |
| 8 | BS_K74PZET7 | medulloblastoma | — | 0.902 |
| 9 | TCGA-HD-A634-01A-11R-A28V-07 | — | — | 0.902 |
| 10 | BS_KVNGNETA | medulloblastoma | — | 0.901 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.450 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.390 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.340 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.270 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.230 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.160 | Temsirolimus | — uncovered |
| SPERMATOGENESIS | 0.160 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.150 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.110 | Remibrutinib | — uncovered |
| PEROXISOME | 0.060 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.010 | Inavolisib | — uncovered |